Recombinant Mouse IgG1e3 Isotype Control Antibody - Fc silent (D265A)

Recombinant mouse IgG1e3 D265A isotype control mAb against E. coli β-galactosidase

InvivoGen provides a recombinant anti-β-Gal-mIgG1e3 monoclonal antibody (mAb) that was previously extracted from hybridoma. It is now expressed and produced in Chinese hamster ovary (CHO) cells, ensuring reliability and lot-to-lot reproducibility. Thereby, common hybridoma-related drawbacks such as the generation of non-relevant mAbs containing aberrant light chains are avoided [1]. This control antibody targets E. coli's β-galactosidase (β-Gal), an irrelevant antigen that is not present in mice.

The sequence of Anti-β-Gal-mIgG1e3 is 100% murine (constant and variable regions), as the original clone (clone T9C6) was raised in mice using a proprietary method. Within the engineered murine IgG1e3 isotype, a point mutation D265A was introduced leading to a complete loss of unwanted Fc-associated effector functions [2]. Altogether, these alterations increase antibody performance and overcome immunogenic events, especially upon repeated mAb injections into mice [3].

InvivoGen provides this antibody in two grades:

• In vitro use: Anti-β-Gal-mIgG1e3
• In vivo use: Anti-β-Gal-mIgG1e3 InvivoFit™

All InvivoFit™ products are handled in a clean room, filter-sterilized, and tested for bacterial contaminants. Additionally, this grade guarantees a low level of endotoxins (<1 EU/mg). The buffer formulation is specifically adapted for in vivo studies.

Key features:

• Targets E. coli β-galactosidase antigen
• Sequence is 100% murine
• Murine IgG1e3 isotype (constant region)
• mIgG1e3 (IgG1 with a replacement of aspartic (D) acid by alanine (A) at position 265 point mutation) is effectorless
• Free from non-relevant mAbs found in hybridoma-based productions
• Produced in animal-free facilities and defined media
• Low aggregation < 5%
• InvivoFit™ grade is available

This antibody is also available in bulk quantity, please contact us

References:

1. Bradbury, A. et al., 2018. When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions. mAbs, 10(4), 539–546.
2. Baudino L. et al., 2008. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J Immunol. 181(9):6664-9.
3. Yamazaki T. et al., 2005. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol. 175(3):1586-92.